BioXcel Therapeutics Inc [NASDAQ: BTAI] loss -10.48% or -0.04 points to close at $0.34 with a heavy trading volume of 30141844 shares.
The daily chart for BTAI points out that the company has recorded -70.94% loss over the past six months.
If we look at the average trading volume of 968.77K shares, BTAI reached to a volume of 30141844 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about BioXcel Therapeutics Inc [BTAI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BTAI shares is $2.81 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BTAI stock is a recommendation set at 2.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for BioXcel Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 21, 2024. While these analysts kept the previous recommendation, Mizuho dropped their target price from $40 to $4. The new note on the price target was released on August 15, 2023, representing the official price target for BioXcel Therapeutics Inc stock. On March 10, 2023, analysts increased their price target for BTAI shares from 20 to 22.
The Average True Range (ATR) for BioXcel Therapeutics Inc is set at 0.06, with the Price to Sales ratio for BTAI stock in the period of the last 12 months amounting to 7.40.
Trading performance analysis for BTAI stock
BioXcel Therapeutics Inc [BTAI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.68. With this latest performance, BTAI shares dropped by -0.29% in over the last four-week period, additionally sinking by -70.94% over the last 6 months – not to mention a drop of -87.68% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BTAI stock in for the last two-week period is set at 42.46, with the RSI for the last a single of trading hit 40.99, and the three-weeks RSI is set at 42.80 for BioXcel Therapeutics Inc [BTAI]. The present Moving Average for the last 50 days of trading for this stock 0.4356, while it was recorded at 0.3571 for the last single week of trading, and 1.0436 for the last 200 days.
BioXcel Therapeutics Inc [BTAI]: A deeper dive into fundamental analysis
BioXcel Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.81 and a Current Ratio set at 1.87.
An analysis of Institutional ownership at BioXcel Therapeutics Inc [BTAI]
There are presently around $8.76%, or 10.96%% of BTAI stock, in the hands of institutional investors. The top three institutional holders of BTAI stocks are: ARMISTICE CAPITAL, LLC with ownership of 2.99 million shares, which is approximately 9.6767%. FMR LLC, holding 2.21 million shares of the stock with an approximate value of $$2.82 million in BTAI stocks shares; and FMR LLC, currently with $$1.24 million in BTAI stock with ownership which is approximately 3.1438%.
